Search

Your search keyword '"Kulkarni, Roshni"' showing total 283 results
Start Over Author "Kulkarni, Roshni" Language english
283 results on '"Kulkarni, Roshni"'

4. Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial

Author

Ragni, Margaret V, Rothenberger, Scott D, Feldman, Robert, Nance, Danielle, Leavitt, Andrew D, Malec, Lynn, Kulkarni, Roshni, Sidonio, Robert, Jr, Kraut, Eric, Lasky, Joseph, Pruthi, Rajiv, Angelini, Dana, Philipp, Claire, Hwang, Nina, Wheeler, Allison P, Seaman, Craig, Machin, Nicoletta, Xavier, Frederico, Meyer, Michael, Bellissimo, Daniel, Humphreys, Gregory, Smith, Kenneth J, Merricks, Elizabeth P, Nichols, Timothy C, Ivanco, Dana, Vehec, Deborah, Koerbel, Glory, and Althouse, Andrew D

Published
2023
Full Text
View/download PDF

12. The current challenges faced by people with hemophilia B.

Author

Miesbach, Wolfgang, von Drygalski, Annette, Smith, Clive, Sivamurthy, Krupa, Pinachyan, Karen, Bensen‐Kennedy, Debbie, Drelich, Douglass, and Kulkarni, Roshni

Subjects
BLOOD coagulation factor IX, HEMOPHILIA, GENETIC disorders, METRORRHAGIA, BLOOD coagulation factors
Abstract

Hemophilia B (HB) is a rare, hereditary disease caused by a defect in the gene encoding factor IX (FIX) and leads to varying degrees of coagulation deficiency. The prevailing treatment for people with HB (PWHB) is FIX replacement product. The advent of recombinant coagulation products ushered in a new era of safety, efficacy, and improved availability compared with plasma‐derived products. For people with severe HB, lifelong prophylaxis with a FIX replacement product is standard of care. Development of extended half‐life FIX replacement products has allowed for advancements in the care of these PWHB. Nonetheless, lifelong need for periodic dosing and complex surveillance protocols pose substantive challenges in terms of access, adherence, and healthcare resource utilization. Further, some PWHB on prophylactic regimens continue to experience breakthrough bleeds and joint damage, and subpopulations of PWHB, including women, those with mild‐to‐moderate HB, and those with inhibitors to FIX, experience additional unique difficulties. This review summarizes the current challenges faced by PWHB, including the unique subpopulations; identifying the need for improved awareness, personalized care strategies, and new therapeutic options for severe HB, which may provide future solutions for some of the remaining unmet needs of PWHB. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A

Author

von Drygalski, Annette, Chowdary, Pratima, Kulkarni, Roshni, Susen, Sophie, Konkle, Barbara A, Oldenburg, Johannes, Matino, Davide, Klamroth, Robert, Weyand, Angela C, Jimenez-Yuste, Victor, Nogami, Keiji, Poloskey, Stacey, Winding, Bent, Willemze, Annemieke, Knobe, Karin, XTEND-1 Trial Group, Hermans, Cédric, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, and UCL - (SLuc) Service d'hématologie

Subjects
Factor VIII, Coagulants, Recombinant Fusion Proteins, von Willebrand Factor, Humans, Hemorrhage, General Medicine, Hemophilia A, Chemoprevention, Drug Administration Schedule, Half-Life
Abstract

BACKGROUND: Efanesoctocog alfa provides high sustained factor VIII activity by overcoming the von Willebrand factor-imposed half-life ceiling. The efficacy, safety, and pharmacokinetics of efanesoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated patients with severe hemophilia A are unclear. METHODS: We conducted a phase 3 study involving patients 12 years of age or older with severe hemophilia A. In group A, patients received once-weekly prophylaxis with efanesoctocog alfa (50 IU per kilogram of body weight) for 52 weeks. In group B, patients received on-demand treatment with efanesoctocog alfa for 26 weeks, followed by once-weekly prophylaxis with efanesoctocog alfa for 26 weeks. The primary end point was the mean annualized bleeding rate in group A; the key secondary end point was an intrapatient comparison of the annualized bleeding rate during prophylaxis in group A with the rate during prestudy factor VIII prophylaxis. Additional end points included treatment of bleeding episodes, safety, pharmacokinetics, and changes in physical health, pain, and joint health. RESULTS: In group A (133 patients), the median annualized bleeding rate was 0 (interquartile range, 0 to 1.04), and the estimated mean annualized bleeding rate was 0.71 (95% confidence interval [CI], 0.52 to 0.97). The mean annualized bleeding rate decreased from 2.96 (95% CI, 2.00 to 4.37) to 0.69 (95% CI, 0.43 to 1.11), a finding that showed superiority over prestudy factor VIII prophylaxis (P

Published
2023

16. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Author

Mahlangu, Johnny, Powell, Jerry S., Ragni, Margaret V., Chowdary, Pratima, Josephson, Neil C., Pabinger, Ingrid, Hanabusa, Hideji, Gupta, Naresh, Kulkarni, Roshni, Fogarty, Patrick, Perry, David, Shapiro, Amy, Pasi, K. John, Apte, Shashikant, Nestorov, Ivan, Jiang, Haiyan, Li, Shuanglian, Neelakantan, Srividya, Cristiano, Lynda M., Goyal, Jaya, Sommer, Jurg M., Dumont, Jennifer A., Dodd, Nigel, Nugent, Karen, Vigliani, Gloria, Luk, Alvin, Brennan, Aoife, and Pierce, Glenn F.

Published
2014
Full Text
View/download PDF

19. Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease

Author

Ragni, Margaret V., Rothenberger, Scott, Feldman, Robert, Nance, Danielle, Leavitt, Andrew D, Malec, Lynn, Sidonio, Jr., Robert F., Kraut, Eric H., Lasky, Joseph L, III, Philipp, Claire S., Angelini, Dana E., Pruthi, Rajiv K., Hwang, Nina, Wheeler, Allison P., Kulkarni, Roshni, Seaman, Craig D., Xavier, Frederico, Machin, Nicoletta C, Meyer, Michael, Bellissimo, Daniel, Smith, Kenneth J., Merricks, Elizabeth P., Nichols, Timothy C., Ivanco, Dana, Vehec, Deborah, Koerbel, Glory, and Althouse, Andrew D.

Published
2022
Full Text
View/download PDF

20. A Retrospective Analysis of the American Thrombosis and Hemostasis Network Dataset Describing Outcomes of Dental Extractions in Persons with Hemophilia.

Author

Messenger, Heather, Kulkarni, Roshni, Recht, Michael, and He, Chunla

Subjects
*HEMOPHILIACS, *DENTAL extraction, *HEMOSTASIS, *THROMBOSIS, *HEMOPHILIA
Abstract

Introduction: dental extractions (DEs) in persons with hemophilia A or B (PWH-A or PWH-B) are often associated with bleeding and needing hemostatic therapies (HTs). Aim: to analyze the American Thrombosis and Hemostasis Network (ATHN) dataset (ATHNdataset) to assess trends, uses and impacts of HT on bleeding outcomes following DEs. Methods: PWH seen at ATHN affiliates who underwent DEs and opted to share their data with the ATHNdataset between 2013–2019 were identified. The type of DEs, use of HT and bleeding outcomes were assessed. Results: Among 19,048 PWH ≥2 years of age, 1157 underwent 1301 episodes of DE. Those on prophylaxis experienced a nonsignificant reduction in dental bleeding episodes. Standard half-life factor concentrates were used more often than extended half-life products. PWHA were more likely to undergo DE in the first 30 years of life. Those with severe hemophilia were less likely to undergo DE than those with a mild disease (OR: 0.83; 95% CI: 0.72–0.95). PWH with inhibitors had statistically significantly increased odds of dental bleeding (OR: 2.09, 95% CI; 1.21–3.63). Conclusion: our study showed that persons with mild hemophilia and younger age were more likely to undergo DE; the presence of inhibitors increased the likelihood of bleeding, while those with prophylaxis and receiving HT experienced a non-statistically significant reduction in bleeding. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Depression and anxiety in persons with Von Willebrand disease.

Author

Roberts, Jonathan C., Kulkarni, Roshni, Kouides, Peter A., Sidonio, Robert F., Carpenter, Shannon L., Konkle, Barbara A., Wu, Joanne, Ullman, Megan M., Curtis, Randall, Baker, Judith R., Crook, Nicole, and Nichol, Michael B.

Subjects
*VON Willebrand disease, *GENERALIZED anxiety disorder, *HEALTH facilities, *ANXIETY, *MENTAL health screening, *MENTAL depression
Abstract

Objective: We assessed sociodemographic and clinical characteristics associated with depression and anxiety in individuals with Von Willebrand disease (VWD) aged ≥12 years. Methods: The study collected data on patients' sociodemographic, joint problems and health‐related quality of life (HRQoL) using EQ‐5D‐3L, 8‐item patient health questionnaire for depression and 7‐item Generalized Anxiety Disorder Questionnaire from participants in seven geographically diverse US haemophilia treatment centres. Results: Analyses included 77 participants. The rates of depression and anxiety were 63.6% and 58.3%, respectively. Persons with low VWF displayed higher rates of depression (86.7%) or anxiety (69.2%) compared to those with VWD (58.1%, p =.04 for depression, and 55.9%, p =.38 for anxiety). Logistic regression analyses demonstrated that having joint problems (odds ratio [OR] = 6.3, confidence interval [CI] = 2.0–20.1) was the most important variable associated with depression, followed by being single, divorced, widowed, or separated in adult participants or parents of participants age < 18 years (OR = 7.0, CI = 1.7–29.0. The most important variable associated with anxiety was being single or lacking a partner (OR = 10.8, CI = 2.5–47.5), followed by age 12–17 years old (OR = 6.7, CI = 1.6–26.9), or having worse health compared to 3‐months ago (OR = 12.3, CI = 1.3‐116.2). Mean covariates adjusted EQ visual analogue scale score was significantly lower among persons with depression (68.77 ± 3.15 vs. 77.58 ± 4.24, p =.03) than those without depression. Conclusions: Our study revealed concerning levels of depression and anxiety in this VWD sample. Lack of social support was determined an important factor associated with depression and anxiety in this sample. Mental health screening is critical in VWD clinical evaluation and care. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementation science.

Author

Byams, Vanessa R., Baker, Judith R., Bailey, Cindy, Connell, Nathan T., Creary, Melissa S., Curtis, Randall G., Dinno, Alexis, Guelcher, Christine J., Kim, Michelle, Kulkarni, Roshni, Lattimore, Susan, Norris, Keri L., Ramirez, Lucy, Skinner, Mark W., Symington, Susan, Tobase, Patricia, Vázquez, Esmeralda, Warren, Beth B., Wheat, Emily, and Buckner, Tyler W.

Published
2023
Full Text
View/download PDF

23. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research to advance the health of people with inherited bleeding disorders with the potential to menstruate.

Author

Baldwin, Maureen K., Ahmadzia, Homa K., Bartlett, Diane L., Bensen-Kennedy, Debbie, Desai, Vidhi, Haley, Kristina M., Herman-Hilker, Sherry L., Kilgore, Amanda M., Kulkarni, Roshni, Lavin, Michelle, Luckey, Shari, Matteson, Kristen A., Paulyson-Nuñez, Kristin, Philipp, Claire S., Ragosta, Sachiko, Rosen, Kimberly, Rotellini, Dawn, and Weyand, Angela C.

Published
2023
Full Text
View/download PDF

32. Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders

Author

Grosse, Scott D., Schechter, Michael S., Kulkarni, Roshni, Lloyd-Puryear, Michele A., Strickland, Bonnie, and Trevathan, Edwin

Subjects
Genetic disorders -- Care and treatment, Genetic disorders -- Patient outcomes, Genetic disorders -- Research, Patients -- Care and treatment, Patients -- Models, Medical care -- Utilization, Medical care -- Research, Medical care -- Demographic aspects
Published
2009

33. Comorbidities, Health-Related Quality of Life, Health-care Utilization in Older Persons with Hemophilia—Hematology Utilization Group Study Part VII (HUGS VII).

Author

Curtis, Randall, Manco-Johnson, Marilyn, Konkle, Barbara A, Kulkarni, Roshni, Wu, Joanne, Baker, Judith R, Ullman, Megan, Jr, Duc Quang Tran, and Nichol, Michael B

Subjects
HEMOPHILIACS, OLDER people, QUALITY of life, HEMOPHILIA treatment, HEMATOLOGY
Abstract

Purpose: We compare the impact of hemophilia on comorbidities, joint problems, health-related quality of life (HRQoL) and health-care utilization between two age groups: 40– 49 years and ≥ 50 years. Patients and Methods: The HUGS VII study recruited persons with hemophilia A or B age ≥ 40 years. Participants completed surveys to collect data on sociodemographic and clinical characteristics, hemophilia treatment regimen, pain, joint problems, comorbidities, HRQoL, depression and anxiety, at baseline and 6-months later. Clinical chart reviews documented hemophilic severity and treatment. Results: The sample includes 69 males, 65.2% aged ≥ 50 years, 75.4% with hemophilia A. Individuals ≥ 50 years were more likely to have mild or moderate hemophilia (68.9% vs 41.7%, P = 0.03) than those 40– 49 years old. Among persons with mild/moderate hemophilia, those ≥ 50 years old reported a higher rate of joint pain (83.9% vs 70.0%, P = 0.34 at baseline, 91.3% vs 57.1%, P = 0.06 at follow up) or range of motion limitation (73.3% vs 60.0%, P = 0.43 at baseline, 73.9% vs 28.6%, P = 0.04 at follow up) than the younger group. Compared to the younger group, the older group reported fewer emergency room visits (4.5% vs 21.7%, P = 0.03), and physical therapy visits (15.9% vs 43.5%, P = 0.01) at baseline. The sample depression rate was 85.7%, but the differences among the age groups were not significant. The mean covariate-adjusted EQ-5D index score was lower in older persons (0.77 vs 0.89, P = 0.02). Conclusion: Older persons with hemophilia in this sample are over-represented by individuals with mild/moderate disease, potentially due to premature death among those with severe disease. Although this group included a larger proportion of individuals with mild disease than the younger group, they experienced lower quality of life, more comorbidities both of aging and of hemophilic arthropathy, and lower rates of health-care utilization. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. Clinical perspectives of emerging pathogens in bleeding disorders

Author

Ludlam, Christopher A., Powderly, William G., Bozzette, Samuel, Diamond, Michael, Koerper, Marion A., Kulkarni, Roshni, Ritchie, Bruce, Siegel, Jamie, Simmonds, Peter, Stanley, Samuel, Tapper, Michael L., and von Depka, Mario

Subjects
HIV patients -- Care and treatment, HIV patients -- Analysis, Blood diseases -- Care and treatment, Blood diseases -- Complications and side effects, Blood diseases -- Analysis
Published
2006

35. Contributors

Author

Abdul-Hussein, Mustafa, Abhyankar, Sunil, Adam, Rodney D., Adams, Paul C., Adesanya, T.M. Ayodele, Agudelo Higuita, Nelson Iván, Ahmed, Omar G., Akst, Lee, Anderson, Kelley P., Andre, Paul, Anstead, Gregory M., Aring, Ann M., Armstrong, Cheryl A., Arshi, Arash, Avalos, Danny, Azar, Cecilio M., Azarbal, Amir, Baeseman, Zachary, Bailey, Justin, Bajaj, Mandeep, Bakhutashvili, Vladimer, Balagué, Federico, Banti, Matthew Michael, Barth, Bradley, Basello, Gina M., Bassaly, Renee, Bassily-Marcus, Adel, Baughn, Julie, Belakovskiy, Aleksandr, Ben-Ami, Ronen, Bencheqroun, Hassan, Bernstein, David I., Bernstein, Jonathan A., Beyer, Caroline, Biggerstaff, Kristin Schmid, Birt, Mitchell, Blum, William, Bolotin, Diana, Bonnema, Rachel A., Borenstein, David, Bossart, Christopher, Bowman, Deidra, Bragg, Dee Ann, Bragg, Scott, Brice, Sylvia L., Briggs, Allyson M., Brill, John, Brown, Rachel, Buckley, Peter F., Burns, Sarah, Byrd, Kenneth P., Cadavid, Diego, Caraccio, Thomas R., Carek, Peter J., Carrion, Andres F., Cass, Amanda S., Castell, Donald O., Catinella, Anthony P., Cayley, William E., Jr., Cerquozzi, Sonia, Cervera, Alvaro, Cetani, Filomena, Chamberlain, Rachel, Chan, Lawrence, Chan, Miriam, Chandramohan, Divya, Chang, Zenas, Chen, Jimmy, Chen, Lin Yee, Chihara, Shingo, Chitlur, Meera, Chohan, Saima, Christensen, Jacob, Chyu, Kuang-Yuh, Cigarroa, Joaquin E., Cleland, Paul, Cline, Matthew, Coates, Laura C., Colenbrander, August, Commins, Ryan, Conageski, Christine, Conly, John, Contini, Carlo, Cooper, Ashley, Cooper, Stacy, Cormier, Allison, Cunha, Burke A., Cunha, Cheston B., Curran, Thomas, Curry, Amy, Daines, Cori L., Damas, Oriana M., Damitz, Beth A., Datta, Nandini, Dattilo, Natalie C., Davaro, Raul, David, Kevin A., de Leon, André, de Leon, Tate, DeCastro, Alexei O., DeGeorge, Katharine C., DeLoughery, Thomas G., Deodhar, Atul, Desai, Urmi, Dessinioti, Clio, Diamond, Michael P., Dion, Christopher, Do, Catherine, Dobbs, Thomas, Donahue, Colleen A., Donnan, Geoffrey A., Dorsch, John N., Dougan, Michael, Douglas, Chad, Dowlatshahi, Dar, Dowler, Shannon, Drevets, Douglas, Dudley, Samuel C., Jr., Duggan, Peter R., Eagle, Kim A., Eck, Leigh M., El Atrouni, Wissam, Elston, Dirk M., Embil, John M., Epstein, Scott K., Evans, Susan, Evens, Andrew M., Fagan, J. Barry, Fairweather, Mark, Falk, Marni J., Faris, Anna, Faugno, Anthony J., III, Faust, Hilary, Fayssoux, Kinder, Feldman, Dorianne, Ferguson, Ian, Fife, Terry. D., Finley, David J., Firnhaber, Jonathon, Fisher, Lynn, Fisher, William E., Fleseriu, Maria, Fletcher, Donald, Foster, Jeffrey Michael, Frank, Jennifer, Freeman, Ellen W., Frenz, David A., Gaba, Ruchi, Gaines, Melissa, Garcia, Mark, Ghany, Marc G., George, Virgilio V., Ghazi, Muhammad Ahmad, Gibney, Geoffrey, Gilbert, Donald L., Gilchrist, Karissa, Gillaspie, Erin A., Gilotra, Tarvinder, Gladwin, Mark T., Gluckman, Stephen J., Goddard, Andrew W., Goerl, Kyle, Gold, Mark S., Goldstein, Amy, González-Fernández, Marlis, Goodwin, Gregory, Gosmanov, Aidar R., Gradoni, Luigi, Graham, Timothy P., Grant-Kels, Jane M., Grdinovac, Kristine, Greenberg, Leslie, Greene, William, Greensher, Joseph, Gregory, David, Greiwe, Justin, Hague, Melissa, Halder, Rebat, Hall, Alan M., Harris, Kari R., Harrison, Taylor B., Hartman, Adam L., Hayes, Erin, Haynes, James W., Heidelbaugh, Joel J., Hinshaw, Molly A., Hockenberry, Brandon, Hohl, Raymond J., Holguin, Therese, Holstein, Sarah A., Holyoak, Michael, Homan, Gretchen, Hommema, Kevin, Hommema, Laurie A.M., Horn, Leora, Hossani-Madani, Ahmad Reza, House, Steven A., Houssayni, Sarah, Hueston, William J., Huettemann, Richard, Huffstetler, Alison, Hunter, Anthony, Ibidapo-Obe, Oyetokunbo, Ing, Alice M., Irwin, Gretchen, Isaac, Daniel, Jackson, Alan C., Jackson-Tarlton, Caitlin, Jacobson, Kurt M., Jaller, Jose A., James, W. Ennis, Jeang, Lauren, Jha, Abhishek, Jia, Xiaoming, Johnson, Casey R., Johnson, Lisa M., Jolissaint, Joshua S., Judson, Marc A., Kadhiravan, Tamilarasu, Kalia, Rachna, Kamprath, Sagar, Kanter, Jessica Rachel, Karnad, Dilip R., Karnchanasorn, Rudruidee, Katsambas, Andreas, Katz, Ben, Katzman, Rebecca, Kaunitz, Andrew M., Keegan, B. Mark, Kellerman, Rick D., Kellermann, Scott, Kelly, Christina M., Khaki, Sheevaun, Kim, Arthur Y., Kim, Haejin, Kirsner, Robert S., Kiwalkar, Sonam, Knoefel, Janice, Kolb, Amanda, Kolla, Bhanu Prakash, Korley, Frederick, Kovalsky, Adrienne N., Krause, Megan, Kraut, Eric H., Krishnamurti, Lakshmanan, Krishnan, Kumar, Kuhlmann, Zachary, Kulkarni, Roshni, Kumar, Seema, Kwaan, Mary R., Kyle, Robert A., Lampton, Lucius M., Lange, Richard A., Langlois, Fabienne, Lau, Christine, Lawrence-Hylland, Susan, Lazaroff, Jake, Lee, Lydia U., Leikin, Jerrold B., Leikin, Scott, Leung, Alexander K.C., Levy-Clarke, Grace, LeWinter, Martin M., Lewis, Jennifer, Li, Ming, Liebenstein, Tyler, Lin, Albert P., Linder, Jeffrey A., Lock, James, Long, M. Chantel, Loo-Gross, Colleen, Lubsen, Julia R., Lun, Ronda, Mahvi, David (Sasha), Maiorella, RosaMarie, Malhotra, Uma, Manlove, Emily, Manson, JoAnn E., Mansukhani, Meghna, Marcocci, Claudio, Margo, Curtis E., Marker, Jason E., Martin, Paul, Mathis, Samuel E., Matson, Kristine, Matza, Mark A., Maxwell, Pinckney J., IV, May, Danica, Mazepa, Gregory Marshall, McClain, Molly, McGrew, Christopher, McGuigan, Christopher Charles, Mehta, Meetal, Meiselman, Mick S., Mercado, Moises, Merrell, Ryan, Meyers, Steven L., Michael, William, Miller, Brian J., Millington, Timothy M., Mirza, Moben, Mofenson, Howard C., Mogensen, Kris M., Moritz, Michael L., Mortada, Rami, Mortaji, Parisa, Moss, Heather E., Moul, Judd W., Muller, Martha, Murinova, Natalia E., Murphy, Michael, Muthusubramanian, Arjun, Nagji, Alykhan S., Naranjo, Laura, Nasim, Rabab, Nazari, Matthew A., Nazeef, Moniba, Neelakantan, Viswanathan K., Neff, Don, Neil, Tara, Nelson, William G., Neschis, David G., Nester, Theresa, Nguyen, Tam T., Nicol, Andrea L., Nieves-Arriba, Lucybeth, North, Crystal, Novac, Andrei, Novelli, Enrico M., Nye, Lauren, Obi, Andrea T., Okeson, Jeffrey P., Oliveira, Carlos R., Ong, Peck Y., Oram, Daniel S., Ortiz, David D., Ozgonenel, Bulent, Pacak, Karel, Padin-Rosado, Jose A., Padungkiatsagul, Tanyatuth, Paladine, Heather L., Pandolfino, John E., Patel, Deval, Patton, Simon, Penna, Gerson O., Penna, Maria Lucia, Perkins, Allen, Peterson, Leah, Petroianu, Georg A., Petronic-Rosic, Vesna M., Phan, Hanna, Pietroni, Mark, Plotnikoff, Gregory A., Pollart, Susan M., Poon, Jennifer, Porter, Andrew S.T., Powell, Charles, Pusateri, Margaret, Quinn, James M., Rahko, Peter S., Rajkumar, S. Vincent, Rajpara, Anand, Ramakrishnan, Kalyanakrishnan, Ramirez, Julio A., Rana, Jatin, Rank, Matthew A., Raoult, Didier, Rapose, Alwyn, Rau, Rachel E., Ravindran, Anita, Regehr, Jared, Reid, Ian R., Rennert-May, Elissa, Rew, Karl, Rezapour, Mona, Rhyne, Amanda, Riese, Martha, Robbins, David C., Robert, Sophie, Robertson, Amy D., Robinson, Malcolm, Roche, William P., Rohrberg, Tessa, Rose, Candice, Rose, Peter G., Ross, Stephen, Roth, Alan R., Ruha, Anne-Michelle, Rundell, Kristen, Said, Adnan, Sairenji, Tomoko, Samson, Susan L., Sanchez, Carlos E., Sangodkar, Sandeep, Santana, Arelis, Sarode, Ravindra, Schatz, Michael, Schevchuck, Alex, Schiller, Lawrence R., Schrager, Sarina, Schuller, Dan, Seashore, Justin, Seery, Amy, Seifert, Steven A., Semel, Jeffery D., Shaffi, Saeed Kamran, Shah, Beejal, Shah, Meera, Shah, Prediman Krishan, Shah, Shenil, Shammo, Jamile M., Shapiro, Eugene D., Sharara, Ala I., Sharma, Sonal, Sheehan, John P., Sherman, Kamille S., Shevy, Laura Elyse, Shew, Sable, Sierpina, Victor S., Sievers, Karlynn, Silk, Hugh, Simon, Lisa, Sinclair, Aaron D., Siraj, Dawd S., Smith, Jeannina, Smith, Zachary L., Soder, Rupal, Sojka, John, Somers, William J., Song, Mihae, Sosa, Nestor, Sowder, Timothy, Speer, Linda, St. Louis, Erik Kent, Stephens, Todd, Stiles, Melissa, Stratakis, Constantine, Stulberg, Daniel, Suárez, José D., Takashima, Masayoshi, Takyar, Varun, Talhari, Carolina, Tang, Jie, Tate, Jessica, Templeton, Kim, Teng, Joyce M.C., Thomson, Joanna, Tillett, William, Timbadia, Paresh J., Tobin, Kenneth, Tsaltas, Theodore T., Unizony, Sebastian H., Unruh, Mark, Uppendahl, Locke, Vallurupalli, Anusha, Van Buren, George, II, van Duin, David, Van Durme, Daniel J., Varlamov, Elena V., Veglia, Megan, Vélez, Christopher, Vercellotti, Gregory, Vincent, Kyle, Vinh, Donald C., Vyas, Jatin Mahesh, Wagner, Tamara, Wakefield, Thomas W., Wald, Arnold, Wald, Ellen R., Walker, Robin A., Wang, Ernest, Wang, Jennifer, Watanabe, Koji, Weber, Ruth, Wehler, Cheryl, Wei, Alice C., Weida, Jane A., Weissman, David N., Welliver, Robert C., Sr., Wester, Rebecca M., Wexler, Randell, Wilamowska, Katarzyna, Williams, Kimberly, Williams, Tracy L., Winterhoff, Boris, Wipperman, Jennifer, Wirtz, Mark W., Wittler, Robert, Wood, Gary S., Worswick, Scott, Wu, Dominic J., Wu, Steve W., Wyre, Hadley, Yakubov, Steven, Yang, Xinghong, Yang, Yul W., Yew, Kenneth S., Yi, Yooni, Yiannias, James A., Young, Natawadee, and Zea Vera, Alonso G.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results